SEC Tracker
Get the app

Xtant Medical Holdings XTNT

Xtant Medical Holdings Q1 FY25: revenue $32.9M, up 18%; diluted EPS $0.00

Form
10-Q
Filed
Period
Importance
Notable

Key figures from this report

These are the numbers Xtant Medical Holdings reported for Q1 FY25, the quarter ended Mar 31, 2025, as tagged in the filing’s XBRL data, each against the same quarter a year earlier. A plain-English reading of this report is not written yet.

  1. Revenue$32.9M+18% from $27.9M in Q1 FY2410-Q income statement, on EDGAR
  2. Net income$58KAgainst −$4.4M in Q1 FY2410-Q income statement, on EDGAR
  3. Diluted EPS$0.00Against −$0.03 in Q1 FY2410-Q income statement, on EDGAR
  4. Cash and cash equivalents$5.0M+11% from $4.5M in Q1 FY2410-Q balance sheet, on EDGAR
  5. Cash from operations$1.3MAgainst −$5.8M in Q1 FY2410-Q cash flow statement, on EDGAR

Every quarter in the financial tables

View on EDGAR

Open in the app

Get an email when Xtant Medical Holdings files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 3841 and related industry codes: the same peer list as the financial tables.

  1. Hyperfine HYPR public float $44M, Jun 30, 2025
  2. Vivani Medical EYES public float $46M, Jun 30, 2025
  3. Vivos RDGL public float $48M, Jun 30, 2025
  4. Alpha Pro Tech APT public float $41M, Jun 30, 2025
  5. Nuo Therapeutics AURX public float $41M, Jun 30, 2025